Clinical Trial Update: Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder [Phase 3]

View source ↗

Summary

Completed Phase 3 trial evaluating adjunctive troriluzule for obsessive-compulsive disorder, with results on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Troriluzule (troriluzule)

Snippet

Sponsor: Biohaven Pharmaceuticals, Inc. | Conditions: Obsessive-Compulsive Disorder | Phase 3 | Status: COMPLETED